Work

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

Year: 2018

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2018.11.017

Authors: Andrea Varga, Sarina Piha-Paul, Patrick A. Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei

Institutions: Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Rutgers Cancer Institute, Institut de Cancérologie de l'Ouest, Merck & Co., Inc., Rahway, NJ, USA (United States), MSD (China) Investment Co., Ltd. (China), Northwestern University

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Merck, Merck Sharp and Dohme

OpenAlex ID: W2903353464

FWCI: 26

Cites: 43

Cited by: 281

Related to: 10